Oramed Pharmaceuticals Inc.

Director's Dealing • Jan 12, 2022

Check this box if no longer subject to Section 16. Form 4 or Form 5

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934		hours per response: 0.5
	or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person* KIDRON NADAV	2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]	(Check all applicable) X Director Officer (give title X	5. Relationship of Reporting Person(s) to Issuer 10% Owner Other (specify
(Last) (First) (Middle) 1185 AVENUE OF THE AMERICAS, THIRD FLOOR	3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022		below) below) President and CEO
(Street) NEW YORK, NY 10036 (City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year) 01/05/2022	Line) X Person	6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	(A) or Amount Price (D)			Transaction(s) (Instr. 3 and 4)
Common Stock	01/03/2022		A	150,000	A	(1)	916,481	D
Common Stock	01/03/2022		F	48,752(2)	D	\$13.89	867,729	D
Common Stock	01/03/2022		A	63,000	A	(3)	930,729(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Code (Instr. 8)	Transaction	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)
Stock Option (right to buy	\$13.89	01/03/2022		A		107,000		(5)	01/03/2032 Common	Stock	107,000	\$0	107,000	D

Explanation of Responses:

1. Represents Common Stock granted by the Issuer that vested upon grant.

2. Payment of tax liability by withholding securities incident to the 150,000 shares of Common Stock granted on January 3, 2022.

3. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 15,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

4. This amendment is being filed to correct an administrative error in the Form 4 filed by Mr. Kidron, which reported that 950,729 shares of common stock are beneficially owned by him following the reported transactions. Mr. Kidron beneficially owned 930,729 shares of common stock following the reported transactions.

/s/ Nadav Kidron 01/11/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

1. The Stock Option will vest in 4 installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.